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Abstract
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of becoming the
5  most common cause of years of life lost globally by 2040. Aggravatingly, CKD is a major cause of
catastrophic health expenditure. The costs of dialysis and transplantation consume up to 3% of the annual
1 2 3
4 5 6 4 7 4
8 9 #
1
2
3
4 th
5
6 st
7
8
9
#
th
Kidney Health for Everyone Everywhere - From Prevention to Detection... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132858/?report=printable
1 of 17 6/25/2020, 4:31 PM
healthcare budget in high-income countries. Crucially, however, the onset and progression of CKD is often
preventable. In 2020, the World Kidney Day campaign highlights the importance of preventive
interventions – be it primary, secondary or tertiary. This complementing article focuses on outlining and
analyzing measures that can be implemented in every country to promote and advance CKD prevention.
Primary prevention of kidney disease should focus on the modification of risk factors and addressing
structural abnormalities of the kidney and urinary tracts, as well as exposure to environmental risk factors
and nephrotoxins. In persons with pre-existing kidney disease, secondary prevention, including blood
pressure optimization and glycemic control, should be the main goal of education and clinical
interventions. In patients with advanced CKD, management of co-morbidities such as uremia and
cardiovascular disease is a highly recommended preventative intervention to avoid or delay dialysis or
kidney transplantation. Political efforts are needed to proliferate the preventive approach. While national
policies and strategies for non-communicable diseases might be present in a country, specific policies
directed toward education and awareness about CKD screening, management and treatment are often
lacking. Hence, there is an urgent need to increase the awareness of the importance of preventive measures
throughout populations, professionals and policy makers.
Keywords: Awareness, detection, kidney diseases, prevention
Introduction
Around 850 million people currently are affected by different types of kidney disorders.[1] Up to one in ten
adults worldwide has chronic kidney disease (CKD), which is invariably irreversible and mostly
progressive. The global burden of CKD is increasing, and CKD is projected to become the 5  most
common cause of years of life lost globally by 2040.[2] If CKD remains uncontrolled and if the affected
person survives the ravages of cardiovascular and other complications of the disease, CKD progresses to
end-stage renal disease (ESRD), where life cannot be sustained without dialysis therapy or kidney
transplantation. Hence, CKD is a major cause of catastrophic health expenditure.[3] The costs of dialysis
and transplantation consume 2–3% of the annual health-care budget in high-income countries; spent on less
than 0.03% of the total population of these countries.[4]
Importantly, however, kidney disease can be prevented and progression to ESRD can be delayed with
appropriate access to basic diagnostics and early treatment including life style modifications and nutritional
interventions.[4,5,6,7,8] Despite this, access to effective and sustainable kidney care remains highly
inequitable across the world, and kidney disease a low health priority in many countries. Kidney disease is
crucially missing from the international agenda for global health. Notably absent from the impact indicators
for the Sustainable Development Goal (SDG) Goal 3. Target 3.4: By 2030 (By 2030, reduce by one third
premature mortality from non-communicable diseases (NCDs) through prevention and treatment and
promote mental health and well-being) and the latest iteration of the Untied Nation (UN) Political
Declaration on NCDs, kidney diseases urgently need to be given political attention, priority and
consideration.[9] Current global political commitments on NCDs focus largely on four main diseases:
cardiovascular disease (CVD), cancer, diabetes, and chronic respiratory diseases. Yet, it is estimated that
55% of the global NCD burden is attributed to diseases outside of this group.[10] Furthermore, kidney
disease frequently co-exists with the 'big' four NCDs, which leads to worse health outcomes. CKD is a
major risk factor for heart disease and cardiac death, as well as for infections such as tuberculosis, and is a
major complication of other preventable and treatable conditions including diabetes, hypertension, HIV and
hepatitis.[4,5,6,7] As the Sustainable Development Goals (SDG) and Universal Health Coverage (UHC)
agendas progress and provide a platform for raising awareness of NCD health care and monitoring needs,
targeted action on kidney disease prevention should become integral to the global policy response.[1] The
global kidney health community calls for the recognition of kidney disease and effective identification and
management of its risk factors as a key contributor to the global NCD burden and the implementation of an
th
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integrated and people's centered approach to care.
Definition and Classification of CKD Prevention
According to the expert definitions including the Center for Disease Control and Prevention,[11] the term
“prevention” refers to activities that are typically categorized by the following three definitions: (1)
Primary Prevention, implies intervening before health effects occur in an effort to prevent the onset of
illness or injury before the disease process begins (2) Secondary Prevention suggests preventive measures
that lead to early diagnosis and prompt treatment of a disease to prevent more severe problems developing
and includes screening to identify diseases in the earliest stages, and (3) Tertiary Prevention indicates
managing disease after it is well established in order to control disease progression and the emergence of
more severe complications, which is often by means of targeted measures such as pharmacotherapy,
rehabilitation, and screening for and management of complications. These definitions have important
bearing in the prevention and management of the chronic kidney disease (CKD), and accurate identification
of risk factors that cause CKD or lead to faster progression to renal failure as shown in Figure 1 are
relevant in health policy decisions and health education and awareness related to CKD.[12]
Primary prevention of CKD
The incidence (new cases) and prevalence (cumulative pre-existing cases) of CKD have been rising
worldwide.[13] This primary level of prevention requires awareness of modifiable CKD risk factors and
efforts to focus healthcare resources on those patients who are at the highest risk of developing new onset
or de novo CKD.
Measures to achieve effective primary prevention should focus on the two leading risk factors for CKD
including diabetes mellitus and hypertension. Evidence suggests that an initial mechanism of injury is renal
hyperfiltration with seemingly elevated glomerular filtration rate, (GFR), above normal ranges. This is
often the result of glomerular hypertension that is often seen in patients with obesity or diabetes mellitus,
but it can also occur after a high dietary protein intake.[8] Other CKD risk factors include polycystic
kidneys or other congenital or acquired structural anomalies of the kidney and urinary tracts, primary
glomerulonephritis, exposure to nephrotoxic substances or medications (such as nonsteroidal anti-
inflammatory drugs), having one single kidney, e.g., solitary kidney after cancer nephrectomy, high dietary
salt intake, inadequate hydration with recurrent volume depletion, heat stress, exposure to pesticides and
heavy metals (as has been speculated as the main cause of Mesoamerican Nephropathy), and possibly high
protein intake in those at higher risk of CKD.[8] Among non-modifiable risk factors are advancing age and
genetic factors such as apolipoprotein 1 (APOL1) gene that is mostly encountered in those with sub-
Saharan African ethnicity, especially among African Americans. Certain disease states may cause de novo
CKD such as cardiovascular and atheroembolic diseases (also known as secondary cardiorenal syndrome)
and liver diseases (hepatorenal syndrome). Table 1 shows some of the risk factors of CKD.
Among measures to prevent emergence of de novo CKD are screening efforts to identify and manage
persons at high risk of CKD, especially those with diabetes mellitus and hypertension. Hence, targeting
primordial risk factors of these two conditions including metabolic syndrome and overnutrition is relevant
to primary CKD prevention as is correcting obesity.[14] Promoting healthier lifestyle is an important means
to that end including physical activity and healthier diet. The latter should be based on more plant-based
foods with less meat, less sodium intake, more complex carbohydrates with higher fiber intake, and less
saturated fat. In those with hypertension and diabetes, optimizing blood pressure and glycemic control has
shown to be effective in preventing diabetic and hypertensive nephropathies. A recent expert panel
suggested that persons with solitary kidney should avoid high protein intake above 1 gram per kilogram
body weight per day.[15] Obesity should be avoided, and weight reduction strategies should be
considered.[14]
Kidney Health for Everyone Everywhere - From Prevention to Detection... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132858/?report=printable
3 of 17 6/25/2020, 4:31 PM
Secondary prevention in CKD
Evidence suggests that among those with CKD, the vast majority have early-stage of the disease. i.e. CKD
Stages 1 and 2 with microalbuminuria (30 to 300 mg/day) or CKD Stage 3B (eGFR between 45 to 60
ml/min/1.73m ).[16] In these persons with preexisting disease, the “secondary prevention” of CKD has the
highest priority. For these earlier stages of CKD, the main goal of kidney health education and clinical
interventions is how to slow disease progression. Uncontrolled or poorly controlled hypertension is one of
the most established risk factors for faster CKD progression. The underlying pathophysiology of faster
CKD progression relates to ongoing damage to the kidney structure and loss of nephrons with worsening
interstitial fibrosis as it happens with sustained hypertension.
The cornerstone of the pharmacotherapy in secondary prevention is the use of angiotensin pathway
modulators, also known as renin-angiotensin-aldosterone system inhibitors (RAASi). These drugs reduce
both systemic blood pressure and intraglomerular pressure by opening efferent arterioles of the glomeruli,
hence, leading to longevity of the remaining nephrons. Low protein diet appears to have a synergistic effect
on RAASi therapy.[17] In terms of the potential effect of controlling glycemic status and correcting obesity
on the rate of CKD progression, there are mixed data. However, recent data suggest that a new class of anti-
diabetic medications known as sodium-glucose cotransporter-2 Inhibitors (SGLT2i) can slow CKD
progression, but this effect may not be related to glycemic modulation of the medication. Whereas acute
kidney injury (AKI) may or may not cause de novo CKD, AKI events that are superimposed on preexisting
CKD may accelerate disease progression.[18] A relatively recent case of successful secondary prevention
that highlights the significance of implementing preventive strategies in CKD is the use of a vasopressin V
(2)-receptor antagonists in Adult Polycystic Kidney Disease (ADPKD).[19]
Tertiary prevention in CKD
In patients with advanced CKD, management of uremia and related comorbid conditions such as anemia,
mineral and bone disorders, and cardiovascular disease is of high priority, so that these patients can
continue to achieve highest longevity. These measures can be collectively referred to as “tertiary
prevention” of CKD. In these individuals, cardiovascular disease burden is exceptionally high, especially if
they have underlying diabetes or hypertension, while they often do not follow other traditional profile of
cardiovascular risk such as obesity or hyperlipidemia. Indeed, in these patients, a so-called “reverse
epidemiology” exist, in that hyperlipidemia and obesity appear to be protective at this advanced stage of
CKD. This could be due to the overshadowing impact of the “protein-energy wasting” (PEW) that happens
more frequently with worsening uremia and which is associated with weight loss and poor outcomes
including cardiovascular disease and death. Whereas many of these patients, if they survive ravages of
PEW and cardiovascular disease, will eventually receive renal replacement therapy in form of dialysis
therapy or kidney transplantation, a new trend is emerging to maintain them longer without dialysis by
implementing conservative management of CKD. However, in some with additional comorbidities such as
metastatic cancers, palliative measures with supportive care can be considered.
Approaches to Identification of Chronic Kidney Diseases
The lack of awareness of CKD around the world is one of the reasons for late presentation of CKD in both
developed and developing economies.[20,21,22] The overall CKD awareness among general population
and even high cardiovascular risk groups across 12 low-income and middle-income countries was less than
10%.[22]
Given its asymptomatic nature, screening of CKD plays an important role in early detection. Consensus
and Positional Statements have been published by International Society of Nephrology,[23] National
kidney Foundation,[24] Kidney Disease Improving Global Outcomes,[25] National Institute of Clinical
2
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Excellence (NICE) Guidelines[26] and Asian Forum for CKD Initiatives.[27] There was lack of trials to
evaluate screening and monitoring of CKD.[28] Currently most will promote a targeted screening approach
to early detection of CKD. Some of the major groups at risk for targeted screening includes: Patients with
diabetes, hypertension, those with family history of chronic kidney disease (CKD), individuals receiving
potentially nephrotoxic drugs, herbs or substances or taking indigenous medicine, patients with past history
of acute kidney injury and individuals older than 65 years.[27,29] CKD can be detected with 2 simple tests:
a urine test for the detection of proteinuria and a blood test to estimate the glomerular filtration rate (GFR).
[24,27]
Given that currently a population screening for CKD is not recommended and it was claimed that it might
add unintended harm to the general population being screened,[28] there is no specialty society or
preventive services group which recommends general screening.[30] Low-income to middle-income
countries are ill-equipped to deal with the devastating consequences of CKD, particularly the late stages of
the disease. There are suggestions that screening should primarily include high-risk individuals, but also
extend to those with suboptimal levels of risk, e.g., prediabetes and prehypertension.[31]
Cost-effectiveness of early detection programs
Universal screening of the general population would be time-consuming, expensive and has been shown to
be not cost-effective. Unless selectively directed towards high- risk groups, such as the case of Chronic
kidney disease of unknown cause (CKDu) in disadvantaged populations,[32] according to a cost-
effectiveness analysis using a Markov decision analytic model, population-based dipstick screening for
proteinuria has an unfavorable cost effectiveness ratio.[33] A more recent Korean study confirmed that
their National Health Screening Program (NHSP) for chronic kidney disease (CKD) is more cost-effective
for patients with diabetes or hypertension than the general population.[34] From an economic perspective,
screening CKD by detection of proteinuria was shown to be cost-effective in patients with hypertension or
diabetes in a systematic review.[35] The incidence of CKD, rate of progression, and effectiveness of drug
therapy were major drivers of cost-effectiveness and thus CKD screening may be more cost-effective in
populations with higher incidences of CKD, rapid rates of progression, and more effective drug therapy.
A Rational Approach to CKD Early Detection
The approach towards CKD early detection will include the decision for frequency of screening, who
should perform the screening and intervention after screening.[21] Screening frequency for targeted
individuals should be yearly if no abnormality is detected on initial evaluation. This is in line with the
Kidney Disease Improving Global Outcomes (KDIGO) resolution that the frequency of testing should be
according to the target group to be tested and generally needs not be more frequent than once per year.[25]
Who should perform the screening is always a question especially when the healthcare professional
availability is a challenge in lower income economies. Physicians, nurses, paramedical staff and other
trained healthcare professionals are eligible to do the screening tests. Intervention after screening is also
important and patients detected to have CKD should be referred to primary care and general physicians
with experience in management of kidney disease for follow up. A management protocol should be
provided to the primary care and general physicians. Further referral to nephrologists for management will
be based on the well-defined protocols.[22,25,27]
Integration of CKD prevention into national NCD programs
Given the close links between CKD and other NCDs, it is critical that CKD advocacy efforts be aligned
with existing initiatives concerning diabetes, hypertension, and cardiovascular disease, particularly in Low
middle income countries (LMIC). Some countries and regions have successfully introduced CKD
prevention strategies as part of their NCD programs. As an example, in 2003, a kidney health promotion
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program was introduced in Taiwan, with its key components including a ban on herbs containing
aristolochic acid, public-awareness campaigns, patient education, funding for CKD research, and the
setting up of teams to provide integrated care.[36] In Cuba, the Ministry of Public Health has implemented
a national program for the prevention of CKD. Since 1996 the program has followed several steps: 1) the
analysis of the resources and health situation in the country; 2) epidemiological research to define the
burden of CKD; and 3); a continuing education for nephrologists, family doctors, and other health
professionals. The main goal has been to bring nephrology care closer to the community through a regional
redistribution of nephrology services and joint management of CKD patients by primary healthcare
physicians and nephrologists.[37] The integration of CKD prevention into NCDs program, has resulted in
the reduction of renal and cardiovascular risks in the general population. Main outcomes have been the
reduction in the prevalence of risk factors, such as low birth weight, smoking, and infectious diseases.
There has been an increased rate of the diagnosis of diabetes and of glycemic control, as well as an
increased diagnosis of patients with hypertension, higher prescription use of renoprotective treatment with
Angiotensin converting enzyme inhibitor (ACEI) and higher rates of blood pressure control.[38] Recently,
the US Department of Health and Human Services has introduced an ambitious program to reduce the
number of Americans developing end-stage renal disease by 25 percent by 2030. The program, known as
the Advancing American Kidney Health Initiative, has set goals with metrics to measure its success; among
them is to put more efforts to prevent, detect, and slow the progression of kidney disease, in part by
addressing traditional risk factors like diabetes and hypertension. To reduce the risk of kidney failure, the
program contemplates advancing public health surveillance and research to identify populations at risk and
those in early stages of kidney disease, and to encourage adoption of evidence-based interventions to delay
or stop progression to kidney failure.[39] Ongoing programs, like the Special Diabetes Program for Indians
(SDPI) represents an important part of this approach by providing team-based care and care management.
Since its implementation, the incidence of diabetes-related kidney failure among American Native
populations decreased by over 40 percent between 2000 and 2015.[40]
Involvement of Primary Care Physicians and Other Health Professionals
Detection and prevention of CKD programs require considerable resources both in terms of manpower and
funds. Availability of such resources will depend primarily on the leadership of nephrologists.[41]
However, the number of nephrologists is not sufficient to provide renal care to the growing number of CKD
patients worldwide. It has been suggested that most cases of non-progressive chronic kidney disease can be
managed without referral to a nephrologist, and specialist referral can be reserved for patients with an
estimated glomerular filtration rate <30 mL min per 1.73 per m2, rapidly declining kidney function,
persistent proteinuria, or uncontrolled hypertension or diabetes.[42] It has been demonstrated that with an
educational intervention the clinical competence of family physicians increases, resulting in preserved renal
function in diabetic patients with early renal disease.[43] The practitioners who received the educational
intervention used significantly more angiotensin-converting enzyme inhibitors, angiotensin-receptor
blockers, and statins than did practitioners who did not receive it. The results were similar to those found in
patients treated by nephrologists.[44] The role of primary health care professionals in the implementation
of CKD prevention strategies in LMIC countries has been recently illustrated.[45]
The e-Learning has become an increasingly popular approach to medical education. Online learning
programs for NCD prevention and treatment, including CKD, have been successfully implemented in
Mexico. By 2015, over 5000 health professionals (including non-nephrologists) had been trained using an
electronic health education platform.[46]
Shortage of Nephrology Manpower – implication on Prevention
The resources for nephrology care remain at critical levels in many parts of the world.
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Even in Western developed countries, nephrologists are frequently in short supply. In a selection of
European countries with similar, predominantly public, health care systems, there was a substantial
variation in the nephrology workforce. Countries like Italy, Greece, and Spain reported the highest ratios,
while countries like Ireland, Turkey and the UK had the lowest ones.[47] In the USA, the number of
nephrologists per 1000 ESRD patients has declined over the years, from 18 in 1997 to 14 in 2010.[48] The
situation in the developing world is even worse. With the exception of Nigeria, Sudan, Kenya and South
Africa, in many countries of sub-Saharan Africa there are fewer than 10 nephrologists. The number of
nephrology nurses and dialysis technicians is also insufficient.[49] In Latin America the average number of
nephrologists is 13.4 pmp. However, there is unequal distribution between countries; those with <10
nephrologists pmp (Honduras, 2.1 pmp; Guatemala, 3.3 pmp; and Nicaragua, 4.6 pmp), and those
exceeding 25 pmp (Cuba, 45.2 pmp; Uruguay, 44.2 pmp; and Argentina, 26.8 pmp).[50]
The causes of this shortage are multiple. Potential contributors to this variation include the increasing
burden of CKD, erosion of nephrology practice scope by other specialists, lack of workforce planning in
some countries relative to others, and the development of new care delivery models.[48] A novel strategy
has been the successful International Society of Nephrology's Fellowship program. Since its
implementation in 1985, over 600 fellows from >83 LMIC have been trained. A significant number of
fellowships were undertaken in selected developed centers within the fellow's own region. In a recent
survey, 85% of responding fellows were re-employed by their home institutions.[51,52]
The Interdisciplinary Prevention Approach
Since 1994, a National Institute of Health consensus advocated for early medical intervention in predialysis
patients. Owing to the complexity of care of CKD, it was recommended that patients should be referred to a
multidisciplinary team consisting of nephrologist, dietitian, nurse, social worker, and health psychologist,
with the aim to reduce predialysis and dialysis morbidity and mortality.[53] In Mexico, a nurse-led,
protocol driven, multidisciplinary program reported better preservation in eGFR and a trend in the
improvement of quality of care of CKD patients similar to those reported by other Multidisciplinary Clinic
(MDC) programs in the developed world. Additionally, more patients started dialysis non-emergently, and
some obtained a pre-emptive kidney transplant. For those unable to obtain dialysis or who choose not to, a
palliative care program is now being implemented.[54] Care models supporting primary care providers or
allied health workers achieved better effectiveness in slowing kidney function decline when compared to
those providing specialty care. Future models should address region-specific causes of CKD, increase the
quality of diagnostic capabilities, establish referral pathways, and provide better assessments of clinical
effectiveness and cost-effectiveness.[55]
Online educational programs for CKD prevention and treatment
Whereas it is important to enhance the promotion and implementation of “Prevention” of kidney disease
and kidney failure amongst healthcare professionals, it is equally important to promote “Prevention” with
education programs for those at risk of kidney disease and kidney failure, and with the general population
at large. It is a stepwise process, from awareness, engagement, participation, empowerment and to
partnership. As highlighted above, in general, the health literacy of the general population is low.
Awareness and understanding of kidney disease are inadequate. Education is key to engaging patients with
kidney disease. It is the path to self-management and patient-centered care. Narva found patient education
is associated with better patient outcomes.[56] Obstacles include the complex nature of kidney disease
information, low baseline awareness, limited health literacy and numeracy, limited availability of CKD
information, and lack of readiness to learn. New education approaches should be developed through
research and quality improvement efforts. Schatell found Web-based kidney education is helpful in
supporting patient self-management.[57] The Internet offers a wealth of resources on education.
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Understanding the types of Internet sources that CKD patients use today can help renal professionals to
point patients in the right direction. It is important that reputable healthcare organizations, preferably at a
national level, facilitate users to have easier access to health information on their websites [Appendix 1].
The mode of communication currently used by patients and the population at large is through the internet -
websites, portals, and other social media, such as Facebook and Twitter. There are also free apps on popular
mobile devices providing education on kidney disease. There is no shortage of information on the internet.
The challenge is how to effectively “push” important healthcare information in a targeted manner, and to
facilitate users seeking information in their efforts to “pull” relevant and reliable information from the
internet. It is important the “pushing” of health information is targeted and specific, relevant for the
condition (primary, secondary or tertiary prevention), and is offered at the right time to the right recipient.
It is possible with the use of information technology and informatics to provide relevant and targeted
information for patients at high risk, coupling the information based on diagnosis and drugs prescribed.
Engagement of professional society resources and patient groups is a crucial step to promote community
partnership and patient empowerment on prevention. Additional resources may be available from charitable
and philanthropic organizations.
Renewed Focus on Prevention and Awareness Raising and Education
Given the pressing urgency pertaining to the need for increasing education and awareness on the
importance of the preventive measures, we suggest the following goals to redirect the focus on plans and
actions:
1. Empowerment through health literacy in order to develop and support national campaigns that bring
public awareness to prevention of kidney disease
2. Population-based approaches to manage key known risks for kidney disease, such as blood pressure
control and effective management of obesity and diabetes
3. Implementation of the World Health Organization (WHO) 'Best Buys' approach including screening
of at-risk populations for CKD, universal access to essential diagnostics of early CKD, availability of
affordable basic technologies and essential medicines and task shifting from doctors to front-line
healthcare workers to more effectively target progression of CKD and other secondary preventative
approaches.
To that end, the motto 'Kidney Health for Everyone, Everywhere' is more than a tagline or wishful thinking.
It is a policy imperative which can be successfully achieved if policy makers, nephrologists and healthcare
professionals place prevention and primary care for kidney disease within the context of their Universal
Health Coverage programs.
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Figure 1
Overview of the preventive measures in chronic kidney disease (CKD) to highlight the similarities and distinctions
pertaining to primary, secondary, and tertiary preventive measures and their intended goals
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Table 1
Risk factors for de novo CKD and pre-existing CKD progression
Open in a separate window
*Many of these risk factors contribute to both de novo CKD and its faster progression and hence are relevant to both
primary and secondary prevention. AIN Acute interstitial nephritis; AKI Acute kidney injury; APOL1 Apolipoprotein
1; ATN Acute tubular necrosis; BPH Benign prostate hypertrophy; CKD chronic kidney disease; CNI Calcineurin
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inhibitor; GN Glomerulonephritis; NASH Non-alcoholic steatohepatitis; NSAIDS Non-steroidal anti-inflammatory
drugs; PPI Proton pump inhibitor
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